The RIT and the stem cell infusions were performed as outpatients; however, patients were closely followed for signs and symptoms of toxicity as they rapidly became lymphopenic and neutropenic following higher doses of 90Y anti-CD20. Patients were managed by the marrow transplantation unit, and if neutropenic fevers or other side effects developed that were not readily manageable as outpatients, patients were admitted to the hospital for additional supportive therapy. Patients were followed regularly for hematological and systemic toxicities, with a special emphasis on hepatic toxicity. Imaging assessments, typically whole-body CT, were performed at 60 days post-90Y RIT and also at approximately 6-month intervals following treatment with response assessed by the International Working Group criteria (IWG), unless there were clinical signs suggesting earlier progression. The study was terminated early due to sale of the drug provider, meaning that completion of the dose escalation, as well as long-term follow-up data are not available.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.